Skip to content

Alexandre Seillier

Schizophrenia Models for Advancing Research and Treatment, Preclinical Research Program, National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic.

3 papers in the library · 3 citations · publishing 2025-2026

Papers

Psilocybin has a narrow therapeutic window as an antidepressant treatment.

Progress in neuro-psychopharmacology & biological psychiatry April 2, 2025 Lenka Seillier, Barbora Čechová, Alexandre Seillier et al. 3 citations

A single dose of psilocybin at 0.32 mg/kg, but not lower or higher doses, produced short- and long-term antidepressant-like effects in Wistar rats, as measured by the forced swim test, and also increased social interaction and sucrose preference. Higher doses of 1.0 and 3.2 mg/kg lacked antidepressant-like activity and instead reduced body temperature, locomotor activity, and weight gain. Brain-derived neurotrophic factor (BDNF) levels in the hippocampus and prefrontal cortex increased linearly with dose, dissociating from the inverted-U-shaped behavioral effects. The findings suggest a narrow therapeutic window for psilocybin, with the intermediate dose providing benefits without adverse effects seen at higher doses.

Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test

Journal of Psychopharmacology June 23, 2026 Lenka Seillier, Alexandre Seillier, Morgan A. Zvolska et al.

Psilocybin produces rapid and sustained antidepressant-like effects in rats, as measured by reduced immobility and increased climbing in the forced swim test. Blocking the 5-HT2B receptor with the antagonist RS-127445 dose-dependently reversed these behavioral effects, indicating that 5-HT2B receptors are necessary for psilocybin's antidepressant-like activity. However, the same antagonist did not affect psilocybin-induced head-twitch responses, a proxy for psychedelic effects, suggesting that the antidepressant-like and psychedelic effects of psilocybin can be dissociated via different serotonin receptor subtypes.

Multidimensional analysis of social withdrawal in the sub-chronic phencyclidine rat model for schizophrenia.

Psychopharmacology April 23, 2026 Stefani Kalli, Alina Davletova, Lenka Seillier et al.

Rats treated with phencyclidine (PCP) to model schizophrenia's negative symptoms showed reduced overall social interaction compared to controls, but the deficit was selective: some behaviors (e.g., Following) were impaired while others were not. A detailed analysis of 42 behaviors revealed that PCP-treated rats also displayed a persistent attentional bias toward the inanimate environment during both habituation and social exposure, suggesting their attention was displaced away from other rats. This multidimensional behavioral approach uncovers a more nuanced phenotype than simple total interaction time, indicating altered attentional allocation as a possible mechanism underlying social withdrawal in this model.